Phase 1 Study of BPN14770 in Participants With Hepatic Impairment and Healthy Controls
← catalyst calendarSponsored by Shionogi (industry) · 4507.T — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
32actual
Sites
3
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-08-30 | actual | When the study began enrolling |
| Primary completion | 2025-11-26 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-11-26 | actual | The whole study's end, after follow-up |
| First posted | 2025-06-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hepatic Impairment
Intervention
- Drug: BPN14770
Primary outcomes
what the primary-completion date above is the date OFArea Under the Plasma Concentration Time Curve Extrapolated from Time 0 to Infinity (AUCinf) of BPN14770
measured Predose up to 240 hours postdose
Maximum Observed Plasma Concentration (Cmax) of BPN14770
measured Predose up to 240 hours postdose
Time Maximum Observed Plasma Concentration (Tmax) of BPN14770
measured Predose up to 240 hours postdose
Permalink · 4507.T's whole pipeline · Catalyst calendar · Every registered study · What changed